MedTrace Logo

Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia

NCT03372447 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2021-03-08

No results posted yet for this study

Summary

Demonstrate the effectiveness of a single dose of a multivitamin complex for the treatment of megaloblastic anemia

Conditions

  • Megaloblastic Anemia Nos
  • Pernicious Anemia

Interventions

DRUG

Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg

Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.

Sponsors & Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Principal Investigators

  • David Gómez Almaguer, MD · Hospital Universitario Dr. José Eleuterio González

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-27
Primary Completion
2018-12-01
Completion
2019-12-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03372447 on ClinicalTrials.gov